Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review
To address the coronavirus disease 2019 (COVID-19) pandemic, several antiviral agents targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed for clinical use. However, antivirals that can be administered irrespective of risk factors were lacking until the approval...
Saved in:
| Main Authors: | Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Masaya Yamato, Takumi Imamura, Hiroki Sakaguchi, Takao Sanaki, Takuhiro Sonoyama, Yuko Tsuge, Takeki Uehara |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-04-01
|
| Series: | Therapeutic Advances in Infectious Disease |
| Online Access: | https://doi.org/10.1177/20499361251321724 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ensitrelvir in Hospitalized Patients with SARS-CoV-2 During the Omicron Epidemic: A Single-Center Observational Study
by: Masaya Yamato, et al.
Published: (2025-04-01) -
Effectiveness of ensitrelvir for cough caused by COVID-19 Omicron variant in patients with asthma
by: Naoyuki Miyashita, et al.
Published: (2025-05-01) -
Characterization of an unusual SARS-CoV-2 main protease natural variant exhibiting resistance to nirmatrelvir and ensitrelvir
by: Dipendra Bhandari, et al.
Published: (2025-07-01) -
Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report
by: Yuki Miyata, et al.
Published: (2025-01-01) -
Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series
by: Shuichi Abe, et al.
Published: (2024-12-01)